The three patients of cohort 2 received a dose of 1×10(9) colony forming units (cfu)/day for up to 28 days of continuous oral dosing.
Dosing of third cohort is expected to commence in the second quarter of 2012 with each patient in the cohort receiving a dose of 1×10(10) cfu/day for up to 28 days.
Marina Biotech president and CEO Michael French said progression through the dose escalation phase will determine the most appropriate once-daily dose for the stable dose phase.
"We believe CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative," French added.